Zevra Therapeutics (ZVRA)
Commercializes U.S.-approved therapies for Niemann-Pick type C disease and certain urea-cycle disorders.
$11.27
vs last close−0.31 (−2.68%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 75.60% | 44.90M shares | |
|---|---|---|---|
| 168 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.38% | 819.0K shares | |
| 10 holders · as of Aug 17, 2026 | |||
| Other | ≈ 23.02% | 13.67M shares | |
| remainder | |||
59.38M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
13F, as of Jun 30, 2026
168 holders · 44.90M shares · 31 new positions · 95 increased · 40 reduced · 20 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 5.11M | 8.60% | +652.4K | Aug 7, 2026 |
| FMR LLC | 4.92M | 8.28% | +1.70M | Aug 13, 2026 |
| Woodline Partners LP | 4.79M | 8.06% | +1.33M | Aug 14, 2026 |
| Vanguard Capital Management LLC | 2.64M | 4.44% | +169.6K | Aug 13, 2026 |
| Nantahala Capital Management, LLC | 1.80M | 3.03% | −724.5K | Aug 19, 2026 |
| State Street Corp | 1.68M | 2.83% | +120.4K | Aug 7, 2026 |
| Geode Capital Management, LLC | 1.54M | 2.59% | +169.1K | Aug 12, 2026 |
| D. E. Shaw & Co., Inc. | 1.31M | 2.20% | +460.5K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 7.60% | 4.08M | 13G | Feb 5, 2025 |
| Woodline Partners LP | 6.20% | 3.48M | 13G | Nov 14, 2025 |
| FMR LLC | 5.50% | 3.21M | 13G | May 6, 2026 |
| Vanguard Capital Management | 5.11% | 3.02M | 13G | Jul 31, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 14, 2026 | Rahsaan Thompsonofficer: Chief Legal & Compliance | Sale | 42,666 | $11.13 | 37,569 |
| Aug 10, 2026 | Corey Michael Wattondirector | Sale | 12,300 | $11.25 | 1,800 |
| Jun 22, 2026 | Rahsaan Thompsonofficer: Chief Legal & Compliance | Sale | 34,557 | $12.68 | 80,235 |
| May 11, 2026 | Rahsaan Thompsonofficer: Chief Legal & Compliance | Sale | 1,794 | $11.30 | 48,125 |
| Feb 9, 2026 | Neil F. McFarlanedirector, officer: President and CEO | Sale | 14,625 | $8.56 | 387,225 |
| Feb 3, 2026 | Joshua Schaferofficer: CCO | Sale | 10,500 | $9.19 | 62,278 |
| Feb 3, 2026 | Timothy J. Sangiovanniofficer: SVP, Finance & Corp Controller | Sale | 3,000 | $9.18 | 29,590 |
| Feb 2, 2026 | Neil F. McFarlanedirector, officer: President and CEO | Sale | 91,000 | $9.38 | 364,350 |
| Jan 30, 2026 | Joshua Schaferofficer: CCO | Sale | 3,375 | $8.83 | 37,444 |
| Jan 30, 2026 | Adrian W. Quartelofficer: Chief Medical Officer | Sale | 4,533 | $8.83 | 9,723 |
House and Senate disclosures
Not reported.